What is the treatment for Takotsubo cardiomyopathy?
What is the treatment for Takotsubo cardiomyopathy?
The initial management of TTS includes dual antiplatelet therapy, anticoagulants, beta-blockers, angiotensin-converting enzyme inhibitors or aldosterone receptor blockers, and statins. Treatment is usually provided for up to three months and has a good safety profile.
What is reverse takotsubo?
Reverse takotsubo, a variant form of takotsubo cardiomyopathy in which the basal and midventricular segments of the left ventricle are akinetic, occurs in a minority of patients [1]. The majority of takotsubo cardiomyopathy patients recover cardiac function within three to six months.
What happens during Takotsubo cardiomyopathy?
Takotsubo cardiomyopathy is a temporary heart condition that develops in response to an intense emotional or physical experience. It’s also known as stress cardiomyopathy or broken heart syndrome. In this condition, the heart’s main pumping chamber changes shape, affecting the heart’s ability to pump blood effectively.
Does ibuprofen help with heart problems?
A: Ibuprofen, such as Advil, Motrin or Ibuprofen, can cause marked worsening of existing hypertension (high blood pressure) or development of new high blood pressure. It can also cause damage to the kidneys (nephrotoxicity), worsening of heart failure, and even heart attack or stroke.
How long does it take to recover from stress cardiomyopathy?
Although complications can occur, most individuals fully recover within one month.
Is Takotsubo cardiomyopathy reversible?
Abstract. Takotsubo cardiomyopathy is an acute, reversible form of left ventricular dysfunction precipitated by emotional or physical stress. The condition is important to recognise as it mimics acute myocardial infarction and acute coronary syndrome. Most patients are female and postmenopausal.
Can you recover from takotsubo cardiomyopathy?
Most individuals that develop takotsubo cardiomyopathy fully recover within one month, and recurrence is rare. However, complications occur in about 20% of patients.